The combination regimen of immunotherapeutics plus bevacizumab and chemotherapy might be a potential approach to improve the limited efficacy of immunotherapy, especially in mCRC patients with high CD8 expression in the tumor microenvironment. This evidence concerns the gene CD8A and neoplasm.